Skip to main content

Advertisement

SpringerLink
Log in

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients. Twenty-five CAD diabetic patients were included. Initially, all patients received aspirin 100 mg/day for 10 days. At day 10, aspirin antiplatelet effect was determined by measuring the collagen/epinephrine closure time (CT) 2 h after the last aspirin dosage and the next morning at 8 a.m.. The aspirin regimen was modified to 100 mg twice daily for patients showing a non-optimal platelet-inhibitory effect (CT < 298 s at 8 a.m.). Persistent high platelet reactivity (HPR) was defined by a CT < 160 s. During the 100 mg/day aspirin regimen, the prevalence of HPR at 8 a.m. was 48%, and only 7 patients (28%) had showed an optimal platelet-inhibitory effect. Bridging to the twice-daily regimen, the HPR was significantly reduced (p = 0.025), and the optimal platelet-inhibitory effect was reached for 3 other patients. Our results showed that 100 mg aspirin twice-daily dosing rather than a once-daily dose significantly improves the aspirin effect on platelet of CAD diabetic patients. However, large prospective studies were needed to confirm whether this strategy will be clinically relevant and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med. 1998;339:229–34.

    Article  CAS  PubMed  Google Scholar 

  2. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.

    Article  CAS  PubMed  Google Scholar 

  3. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet. J Thromb Haemost. 2007;5:490–6.

    Article  CAS  PubMed  Google Scholar 

  4. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30(Suppl 1):s4–s41.

    Google Scholar 

  5. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

  6. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Google Scholar 

  7. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30:1279–86.

    Article  CAS  PubMed  Google Scholar 

  8. Santos MT, Vallés J, Aznar J, Lago A, Sanchez E, Cosin J, et al. Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med. 2006;147:220–7.

    Article  CAS  PubMed  Google Scholar 

  9. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541–7.

    Article  PubMed  Google Scholar 

  10. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593–9.

    Article  PubMed  Google Scholar 

  11. Addad F, Chakroun T, Abderazek F, Ben-Farhat M, Hamdi S, Dridi Z, et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. J Thromb Thrombolysis. 2010;29(1):108–13.

    Google Scholar 

  12. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56(12):3014–9.

    Article  CAS  PubMed  Google Scholar 

  13. Chakroun T, Addad F, Abderazek F, Ben-Farhat M, Hamdi S, Gamra H, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res. 2007;121:413–8.

    Article  CAS  PubMed  Google Scholar 

  14. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32:531–40.

    Article  CAS  PubMed  Google Scholar 

  15. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al., Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.

    Google Scholar 

  16. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;12:3264–72.

    Article  Google Scholar 

  17. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009;103:20A–6A.

    Article  CAS  PubMed  Google Scholar 

  18. Crescente M, Di Castelnuovo A, Iacoviello L, De Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost. 2008;99:1129–31.

    CAS  PubMed  Google Scholar 

  19. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28:s25–32.

    Article  CAS  PubMed  Google Scholar 

  20. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002;99:7634–9.

    Article  CAS  PubMed  Google Scholar 

  21. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A, et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res. 2005;116:465–70.

    Article  CAS  PubMed  Google Scholar 

  22. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986;68:886–91.

    CAS  PubMed  Google Scholar 

  23. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation. 1990;82:897–902.

    CAS  PubMed  Google Scholar 

  24. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. TRITON-TIMI 38 investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626–36.

    Google Scholar 

  25. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665–73.

    Google Scholar 

  26. Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C, et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost. 2010;103(3):516–24.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The study was supported by Tunisian Ministry of Public Health.

Conflict of interest

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Cardiac Thrombosis Research Unit, Department of Cardiology A, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia

    Faouzi Addad, Zohra Dridi & Habib Gamra

  2. Research Unit “Platelet function Study”, UR.06SP05, Regional Center of Blood Transfusion, Sousse, Tunisia

    Tahar Chakroun

  3. Department of Biological Haematology, Tenon Hospital, ER2 UPMC, Paris, France

    Ismail Elalamy

  4. Haematology’s Laboratory, Fattouma Bourguiba University Hospital, Monastir, Tunisia

    Fatma Abderazek, Saoussen Chouchene, Gregoris T. Gerotziafas, Mohamed Hatmi & Mohsen Hassine

Authors
  1. Faouzi Addad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tahar Chakroun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ismail Elalamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatma Abderazek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Saoussen Chouchene
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zohra Dridi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gregoris T. Gerotziafas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohamed Hatmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohsen Hassine
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Habib Gamra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faouzi Addad.

About this article

Cite this article

Addad, F., Chakroun, T., Elalamy, I. et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol 92, 296–301 (2010). https://doi.org/10.1007/s12185-010-0652-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0652-3

Keywords

Search

Navigation